How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Optic Neuritis Treatment Market
- By Treatment Type: Corticosteroids, Plasma Exchange Therapy, Immunosuppressive Agents, Intravenous Immunoglobulin (IVIG), Monoclonal Antibodies
- By Route of Administration: Intravenous, Oral, Intramuscular
- By Patient Age Group: Pediatric, Adult, Geriatric
- By Disease Severity: Acute Optic Neuritis, Chronic Optic Neuritis, Recurrent Optic Neuritis
- By End User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Home Healthcare
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Corticosteroids leads By Treatment Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 17 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 294 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.175 →
- 12 Company Profiles 17 players: SWOT & benchmarking p.183 →
Full report · locked preview
Everything inside the Optic Neuritis Treatment Market report
A complete, evidence-based study - 12 chapters and 123 sections covering market size, segmentation across 5 axes, regional analysis and 17 company profiles, forecast to 2033.
Segmentation covered
Treatment Type 5
Route of Administration 3
Patient Age Group 3
Disease Severity 3
End User 4
Companies profiled
Novartis AG
Roche Holding AG
Biogen Inc.
Sanofi S.A.
Horizon Therapeutics plc
Alexion Pharmaceuticals
Inc. (a subsidiary of AstraZeneca)
Sandoz (a Novartis division)
Teva Pharmaceutical Industries Ltd.
Mylan N.V. (now part of Viatris)
Bayer AG
Pfizer Inc.
+5 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
17 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Novartis AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Roche Holding AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Biogen Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Sanofi S.A.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Horizon Therapeutics plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Alexion Pharmaceuticals
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Inc. (a subsidiary of AstraZeneca)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Sandoz (a Novartis division)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Teva Pharmaceutical Industries Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Mylan N.V. (now part of Viatris)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Bayer AG
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Pfizer Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Eisai Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.227 →Genentech
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Inc. (a member of the Roche Group)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Celgene Corporation (a Bristol-Myers Squibb company)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Mallinckrodt Pharmaceuticals
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.250 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$6,513M by 2033 · 5.0% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Corticosteroids34.4
- Plasma Exchange Therapy9.7
- Immunosuppressive Agents18.5
- Intravenous Immunoglobulin (IVIG)15.0
- Monoclonal Antibodies22.4
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,451M → $1,911M · 3.5%
Europe$1,011M → $1,648M · 6.3%
Asia Pacific$923.1M → $1,411M · 5.5%
Latin America$571.4M → $826.0M · 4.7%
Middle East and Africa$439.6M → $578.1M · 3.5%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →4.992026
4.992027
5.022028
5.032029
5.032030
5.042031
5.062032
5.072033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Novartis AG15.1
- Roche Holding AG19.0
- Biogen Inc.7.9
- Sanofi S.A.12.1
- Horizon Therapeutics plc12.3
- Alexion Pharmaceuticals5.6
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Treatment Type24.5%
Route of Administration23.2%
Patient Age Group9.6%
Disease Severity26.4%
End User16.3%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America30.0
- Europe25.8
- Asia Pacific22.1
- Latin America13.0
- Middle East and Africa9.1
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Novartis AG | 91 | 97 | 79 | 84 | 86 | 87 | 87 |
| Roche Holding AG | 69 | 71 | 77 | 83 | 78 | 85 | 77 |
| Biogen Inc. | 70 | 75 | 80 | 65 | 75 | 72 | 73 |
| Sanofi S.A. | 80 | 65 | 71 | 82 | 61 | 78 | 73 |
| Horizon Therapeutics plc | 66 | 61 | 67 | 71 | 55 | 57 | 63 |
| Alexion Pharmaceuticals | 70 | 50 | 51 | 58 | 64 | 70 | 61 |
| Inc. (a subsidiary of AstraZeneca) | 47 | 54 | 47 | 41 | 47 | 56 | 49 |
| Sandoz (a Novartis division) | 56 | 39 | 45 | 46 | 48 | 55 | 48 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Novartis AG
- Roche Holding AG
- Biogen Inc.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Novartis AG | ✓ | ✓ | ✓ | ◐ | ✓ | ✓ |
| Roche Holding AG | ◐ | ◐ | ✓ | ✓ | ✓ | ✓ |
| Biogen Inc. | − | ◐ | ✓ | − | ◐ | ◐ |
| Sanofi S.A. | ◐ | ◐ | ◐ | ◐ | ◐ | ✓ |
| Horizon Therapeutics plc | − | ◐ | ◐ | ✓ | ◐ | − |
| Alexion Pharmaceuticals | ✓ | ◐ | ◐ | − | ◐ | ◐ |
| Inc. (a subsidiary of AstraZeneca) | − | − | − | − | ◐ | ◐ |
| Sandoz (a Novartis division) | ◐ | − | − | − | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Novartis AG87
2Roche Holding AG77
3Biogen Inc.73
4Sanofi S.A.73
5Horizon Therapeutics plc63
6Alexion Pharmaceuticals61
7Inc. (a subsidiary of AstraZeneca)49
8Sandoz (a Novartis division)48
Competitive tiers
§8.4 · p.172 →Leader1
Set the pace on share, breadth and innovation.
Novartis AG
Challenger3
Strong scale, closing on the leaders.
Roche Holding AGBiogen Inc.Sanofi S.A.
Contender2
Focused players with pockets of strength.
Horizon Therapeutics plcAlexion Pharmaceuticals
Niche2
Specialists in a single segment or region.
Inc. (a subsidiary of AstraZeneca)Sandoz (a Novartis division)
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Treatment Type in North America, then scale across Optic Neuritis Treatment Market — a $487M beachhead inside a $8.31B market.
Beachhead (SOM)$487Mobtainable near-term
Serviceable (SAM)$3.16Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale3 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion92 fit
Corticosteroids
Best fit — highest urgency & budget in Treatment Type.
Economic buyer81 fit
Plasma Exchange Therapy
Strong fit — clear ROI and a fast path to value.
End user66 fit
Immunosuppressive Agents
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Treatment Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Route of Administration & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Patient Age Group
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales45%
Partner / channel29%
Digital / self-serve19%
Marketplaces6%
Positioning & messaging
§GTM 2 · p.194 →For Treatment Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Optic Neuritis Treatment Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified39%
Sales qualified21%
Evaluation13%
Closed-won7%
$12.7KCAC
$56KLTV
4.4:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Optic Neuritis Treatment Market is a high-growth opportunity — $10.3B by 2033, compounding at 10.2%.
TAM · 2025$4.74Btoday
TAM · 2033$10.3Bforecast
CAGR10.2%2027–2033
Cumulative$64.8Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$10.3BTotal addressable market
SAM$4.02BServiceable available market
SOM$883MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →10.2% CAGR
Demand compounds through 2033, outpacing GDP across Treatment Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Treatment Type moving from early to mainstream — durable secular demand.
Consolidation upside
17+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$10.3BLarge & growingTAM by 2033 at 10.2% CAGR
$4.02BServiceable nowreachable with today’s model
$883MBeachhead winobtainable near-term share
17+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$8.03BBear6.6% CAGR
$10.3BBase10.2% CAGR
$13.2BBull13.4% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Route of Administration optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Optic Neuritis Treatment Market — a $9.68B market by 2033. Plan: grow share from 8.7% to 16.1%.
Market size · 2033$9.68Btotal addressable
Market CAGR8.6%2027–2033
Target share16.1%from 8.7% today
Revenue ambition$1.56Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.7% | 16.1% | On track |
| Revenue | $923M | $1.56B | At risk |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Behind |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | At risk |
| Gross margin | 36.3% | 41.2% | Ahead |
| Customer retention | 87.4% | 95.8% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Treatment Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Route of Administration capability
A defensible second engine — invest in Route of Administration to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Treatment Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Route of Administration
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $195M capacity & capability investment
- Greenlight bolt-on M&A in Route of Administration
- Authorise North America expansion plan
- Fund R&D program for Treatment Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossBehind
- Input-cost & supply riskOn track
- Regulatory / policy changeAt risk
- Execution & talentBehind
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Optic Neuritis Treatment Market conversation — a $1.13B market you can size, segment and defend in minutes.
Market size · 2033$1.13Btotal opportunity
Growth4.9%CAGR to 2033
Addressable buyers1,141+accounts in scope
Typical ROI6.1×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Treatment Type
Goal Grow share in Treatment Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.1×return on cost, year one
< 4 mopayback period
$65K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
17+players profiled in this market
Coverage includes
Novartis AGRoche Holding AGBiogen Inc.Sanofi S.A.Horizon Therapeutics plcAlexion PharmaceuticalsInc. (a subsidiary of AstraZeneca)Sandoz (a Novartis division)+9 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Optic Neuritis Treatment Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Optic Neuritis Treatment Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Optic Nerve Disorders Treatment Market
Market size, share, segmentation and regional forecast.
$6.3B market · 2025 base year
View reportOptical Workstations Market
Market size, share, segmentation and regional forecast.
$2.9B market · 2025 base year
View reportOptical Trial Frame Market
Market size, share, segmentation and regional forecast.
$406M market · 2025 base year
View reportOptical Surgical Microscope Market
Market size, share, segmentation and regional forecast.
$1.2B market · 2025 base year
View reportOptical Stereo Microscope Market
Market size, share, segmentation and regional forecast.
$5.0B market · 2025 base year
View reportOptical Safety Equipment Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportOptical Reticle for Microscope Market
Market size, share, segmentation and regional forecast.
$4.1B market · 2025 base year
View reportOptical Quantum Blood Therapy Machine Market
Market size, share, segmentation and regional forecast.
$5.2B market · 2025 base year
View reportOptical Quantum Blood Therapy Equipment Market
Market size, share, segmentation and regional forecast.
$5.3B market · 2025 base year
View reportOptical Pulse And Heart Rate Sensor Market
Market size, share, segmentation and regional forecast.
$4.9B market · 2025 base year
View reportOptical Preclinical Imaging Market
Optical Preclinical Imaging Market is valued at USD 1.12 Billion in 2025 and is expected to rea…
$1.1B market · 2025 base year
View reportOptical Preclinical Imaging Devices Market
Market size, share, segmentation and regional forecast.
$1.0B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.